1 Medical Cannabis & PTSD; A TRIPLE-BLIND PHASE 2 CLINICAL TRIAL EXAMINING THE EFFICACY OF CANNABIS OF VARIOUS CHEMICAL COMPOSITION ON THE SYMPTOMS OF PTSD Philippe Lucas, MA, PhD Student VP of Patient Advocacy, Tilray Graduate Scholar, Centre for Addictions Research of BC
2 Medical Cannabis in Canada R. v. Parker (2000) - constitutional right to choose cannabis as medicine without fear of criminal sanction. In 2001, the Marihuana Medical Access Regulations (MMAR). To date, approximately 60,000 Canadians have obtained an authorization to possess cannabis for medical purposes. 1 million Canadians used cannabis for self-defined medical conditions. (Adlaf, Begin & Sawka, 2005; Belle-Isle & Hathaway, 2007)
3 Canadian Medical Marihuana System MMAR ENDED MARCH 31, 2014 MMPR STARTED APRIL 1, 2014 Health Canada Santé Canada
4 About Tilray Tilray is a Health Canada licensed producer of medical cannabis In April 2014, we began operating a state-of-the-art, $30 million, 60,000 square foot research and production facility employing more than 140 people from the greater Nanaimo area.
5 Tilray Research Program Phase 2 placebo-controlled clinical trial agreement with the University of British Columbia to examine the therapeutic potential of medical cannabis on the symptoms of PTSD. 42 participants; military and police veterans and other survivors of physical violence. Study will compare vaporized cannabis of varying cannabinoid concentrations to placebo. Final ethics approvals in place; recruiting about to begin. Pilot studies of Tilray cannabis-based extracts and preparations Adult Epilepsy, Ontario Brain Institute Nausea/vommitting in oncological treatment, New South Wales, Australia Patient patterns of use and cannabis substitution research Tilray Observational Patient Survey (TOPS) 20+ sites, >1000 patients
6 Dried Cannabis Flower There are over 100 unique cannabinoids, the most abundant of which are -9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabinoids are thought to exert their physiological effects via the endocannabinoid system. THC binds with high affinity to CB1R in the brain, by which it mediates its psychoactive effects. Cannabinoid receptors regulate: memory, sleep, anxiety, mood, stress response, inflammation.
7 Rationale for Cannabis in the Treatment of PTSD Preliminary studies (open-label and observational) suggest a strong potential for the treatment of PTSD with medical cannabis. Cannabis was associated with a 75% reduction in 3 areas of PTSD symptoms (reexperiencing, avoidance, arousal) compared to cannabis abstinent participants. (Greer, Grob, & Halberstadt, 2014). Nabilone, a synthetic cannabinoid, has been shown to be effective in reducing PTSD symptoms including nightmares and insomnia. (Fraser, 2009; Cameron, Watson, & Robinson, 2014). Medical cannabis use has been associated with reductions in the use of opioids, alcohol, tobacco, and illicit substances. (Lucas et al, 2016)
8 Tilray Patient Survey: Primary Illness & Symptoms 107 question survey available online in French and English for 2 weeks in July 2015, with 271 responses received. Primary Illness (n=271) 36% Chronic Pain 12% Arthritis 7% Psychiatric Disorder 7% PTSD 7% Insomnia 6% GI Disorder 5% Headache 4% Crohn s Disease 4% MS 3% Cancer/leukemia 2% Brain Injury Primary Symptoms (n=270) 73% Chronic pain 60% Stress 57% Insomnia 47% Depression 32% Headache 29% Appetite Loss 29% Nausea 27% Spasm 5% Memory Loss 4% Seizures 3% Intraocular Eye Pressure
9 Substitution Effect, Tilray Patient Survey Have you ever used cannabis as a substitute for: Prescription drugs: 63% Alcohol: 25% Cigarettes/tobacco: 12% Illicit drugs: 3%
10 Substitution Effect; Prescription Drugs Substitution by Class of Prescription Drug (n=308) Class # % Oxy/OxyNeo/Percocet Antidepressants (SSRIs/SNRIs) Codeine Derivatives Benzodiazepines Hydromorphone/morphine 20 6 Sleep Aids 18 6 Other Pain (Tramadol/NSAIDS/other opiates) Opioids are the pharmaceuticals most cited by patients who report substituting for prescription drugs, making up over 30% of the total drugs reported.
11 Cannabis Substitution Effect According to Veterans Affairs Canada, significant increase in the use of medical cannabis by patients is paralleled by a nearly 30% decrease in the use of benzodiazapines and a 16% decrease in the use of opioids. (Mike Hager, Globe & Mail, June 6th, 2016) Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95%CI, 37.5%to 9.5%; P=.003) compared with states without medical cannabis laws. (Bachhuber et al. JAMA, 2014) Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. In medical cannabis states, the number of Medicare prescriptions to seniors dropped for drugs that treat pain, depression, anxiety, nausea, psychoses, seizures and sleep disorders. For pain, the annual number of daily doses prescribed per physician fell by more than 11%. (Bradford & Bradford, Health Affairs, 2016)
12 Medical Cannabis & PTSD - Protocol Design Randomized clinical trial Placebo-controlled with 2 active treatments Crossover design from Stage 1 to 2 Triple-blinded 42 participants 2 treatment phases and 3 periods of cannabis abstinence Primary Objective: To compare the independent effects of two active concentrations of vaporized cannabis to placebo on PTSD symptom severity measured by changes in CAPS-5 total scores during three weeks of ad-libitum self-administration during Stage 1 of the study protocol.
13 Protocol Design Continued... RESEARCH QUESTION: Is 10% THC and/or 10% THC/10% CBD more effective than placebo cannabis in reducing symptoms of PTSD, anxiety, depression, and improving sleep and psychosocial functioning among participants? PROTOCOL VISIT SCHEDULE: Initial abstinence of 2 weeks, followed by 3 weeks of placebo or active drug use in Stage 1, then 2 week wash-out, followed by 3 weeks on active drug in Stage 2, then 2 weeks wash-out, followed by a 6 month long-term follow up. PROCEDURES: During weekly site visits participants will be provided with 7 containers containing 2 grams of cannabis each, and can vaporize up to 2 grams per day, returning unused material so we can track actual dosages. Participants will use the Mighty Medic vaporizer, a Class 2 medical device in Canada.
14 Randomization Design STAGE 1 RANDOMIZATION STAGE 2 RANDOMIZATION T100 N = 7 Placebo N = 14 T200 N = 7 Screening T100 (THC/CBD) N = 14 T200 N = 14 T200 (High THC) N = 14 T100 N = 14
15 Significance This is the largest medical cannabis clinical trial to take place in Canada in over 30 years, and the first time Canadian clinical trial has been conducted to study the therapeutic potential of cannabis on a mental health condition. If cannabis proves to have therapeutic value in this population, it would add another tool to the very limited tool-belt physicians currently have in treating PTSD, and could help inform VAC and Canadian military policies re. medical cannabis and PTSD. Substitution effect: independent research and recent data from VAC suggests that an increased use of medical cannabis by vets with PTSD is also accompanied by a decline in the use of benzodiazapines and opioids. It may also be associated with a reduction in alcohol, tobacco and illicit drug use. No matter what the outcomes of this study, further research is necessary to better understand the mechanisms at work in regards to cannabis and PTSD.
16 Maria Tilray s First Patient Maria is a former Royal Canadian Mounted Police officer who was injured in the line of duty, resulting in PTSD, chronic pain, a 60% loss of function in her left hand and the numbing symptoms of Raynaud s disease. Maria's Story
17 QUESTIONS? Philippe Lucas, MA, PhD Student VP of Patient Advocacy, Tilray Graduate Scholar, Centre for Addictions Research of BC
18 Pharmacodynamic Effects of THC & CBD The pharmacodynamic effects of THC include: The pharmacodynamic effects of CBD include: Analgesic Muscle relaxant Anti-emetic Appetite stimulating Psychoactive effects Immunomodulant Analgesic Muscle Relaxant Anxiolytic Neuroprotective Anti-oxidant Anti-psychotic activity
19 Summary of Visits SCREEN ENROLL STAGE 1 CESSATION STAGE 2 CESSATION STAGE 3 LTFU Screen 1 and Screen 2 visits 2 week cessation period Enrollment of participant into study Introductory Session 1 Visits 2 4 Cessation 1 start 2 week period of abstinence Stage 2 Baseline Introductory Session 2 Visits 7 9 Cessation 2 start 2 week period of abstinence Long-term Follow-up Baseline (LTFU Baseline) Optional: up to 8 weekly visits (Visit11 18) if participants consent to participate If participants do not consent to participate, they will move into the LTFU phase of the study LTFU visit after 6 month period
20 Post Traumatic Stress Disorder (PTSD) PTSD is characterized by an inability to recover from a stress reaction following exposure to a traumatic event. Diagnosis requires specific types of trauma exposure: 1. Directly experiencing a traumatic event. 2. Witnessing an event occur to others. 3. Learning that an event occurred to someone else. 4. Exposure to aversive details of traumatic event(s) (e.g. first responders, police). Systems Include: Avoidance social isolation, anhedonia Hyperarousal anxiety, irritability, insomnia Re-experiencing symptoms dreams, memories Negative alterations in cognition and mood *Approximately 700,000 Canadians have been diagnosed with PTSD.
21 Questionnaires Completed at Visits Some questionnaires and assessments will be administered by the investigator or delegated staff according to the protocol. These questionnaires will be completed on paper by the site staff and transcribed into REDCap. These questionnaires include: Questionnaire STOP-Bang Questionnaire CSSRS GWB TLFB SCID CAPS 5 GAF Reason for Assessment Eligibility criteria Depression Quality of life Cannabis disorder Distress tolerance Marijuana withdrawal Sleep quality Anxiety and depression
22 Additional Questionnaires Questionnaire BD II WHO-QOL CUDIT-R DTS Behavioral Checklist PSQI IDAS CTS2S IPF PCL-5 BAI Bite LTFU Reason for Assessment Eligibility criteria Depression Quality of life Cannabis disorder Distress tolerance Marijuana withdrawal Sleep quality Anxiety and depression Conflict tactics in relationships Psychosocial functioning PTSD Anxiety Irritability The effect of the study treatment
23 Actigraphy Actigraphy is an objective assessment to measure sleep parameters and will be used over the course of the study to evaluate changes in sleep. To record sleep, the actigraphy device will be worn on the wrist like a watch to estimate sleep parameters. The measures that will be reported include: time to bed, time out of bed, latency, percentage of efficiency, total time in bed (min), total sleep time (min), wake after sleep onset, number of awakenings, average awakenings (min). Actigraphy has been well validated for the assessment of nighttime sleep parameters across age groups.
24 The MMPR The Marihuana for Medical Purposes Regulations (MMPR) The most significant change in medical cannabis access since 2001, the MMPR were implemented by Health Canada in December 2012, and went into full effect on April 1 st Simplified/decentralized application process NPs can prescribe (maybe) Multiple Licensed Producers Increased quality control Increased strain/symptom awareness
25 Current PTSD Treatments Psychotherapy: Exposure-based interventions have the strongest evidence and include Cognitive Processing Therapy (CPT) and Prolonged Exposure Therapy (PET). These therapies are considered standard psychosocial interventions for PTSD treatment but are associated with high rates of dropout and non-response. Medications: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-and-norepinephrine reuptake inhibitors (SNRIs). In Canada, Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is approved as a PTSD treatment by Health Canada. A significant percentage of PTSD patients fail to respond adequately to established PTSD psychotherapies and treatments or respond in ways that are clinically inadequate. (Brady et al., 2000; Resick & Schnicke, 1992).
Cannabidiol as a potential treatment for anxiety disorders Esther Blessing, MD PhD Overview History and of cannabidiol (CBD) and cannabis Safety and tolerability of CBD CBD pharmacology Clinical need for
MEDICAL CANNABIS IN MINNESOTA MINNESOTA ACADEMY OF PHYSICIAN ASSISTANTS MARCH 18, 2016 TOM ARNESON, MD, MPH MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program
Barriers to Access for Canadians who Use Cannabis for Medical Purposes HigHligHts from: Belle-isle, l., Walsh, Z., Callaway, C., lucas, P., Capler, r., Kay, r., Holtzman, s., marshall, J., stratton, t.
MEDICAL MARIJUANA: WHAT S THE EVIDENCE? L A U R A A. M A R K L E Y, M D B O A R D - C E R T I F I E D I N P E D I A T R I C S / G E N E R A L P S Y C H I A T R Y / C H I L D & A D O L E S C E N T P S Y
Best Practices in Prescribing Benzodiazepines Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Objectives To review current practice guidelines in benzodiazepine prescribing
Understanding Therapeutic Cannabis If we know there is suffering and do nothing to alleviate it, we ourselves become the tormentors Primo Levi Qualifying Conditions in New Hampshire Cancer Glaucoma Positive
PATIENT INTAKE FORM Name: Last Name First Name Date of Birth: / / Gender: Male Female Address: Town: State: Zip Code: MMJ Card #: Exp. Date: Drivers License #: Exp. Date: Home Phone: Cell: Email: Primary
Medical Marijuana Questions from Part 1: 1. is a plant species, variety known as hemp. a. Cannabis sativa Linnaeus b. Cannabis sativa c. Cannabis indica d. Cannabis Lemark 2. The major psychoactive compound
MEDICAL CANNABIS IN MINNESOTA EPILEPSY & SEIZURES WELLNESS EXPO APRIL 16, 2016 MICHELLE LARSON, MPA MDH OFFICE OF MEDICAL CANNABIS 2014: Minnesota becomes 22 nd state with a medical cannabis program State
MAPS Study MP-10 1 Study Synopsis A Randomized, Triple-Blind, Phase 2 Pilot Study with an Open-Label Lead-in Comparing 3 Different Doses of MDMA in Conjunction with Manualized Psychotherapy in 20 Subjects
College of Physicians and Surgeons of British Columbia Cannabis for Medical Purposes Preamble This document is a standard of the Board of the College of Physicians and Surgeons of British Columbia. College
Parkland College A with Honors Projects Honors Program 2012 Post-traumatic Stress Disorder Nicole Smith Parkland College Recommended Citation Smith, Nicole, "Post-traumatic Stress Disorder" (2012). A with
Post-Traumatic Stress Disorder (PTSD) Among People Living with HIV Milton L. Wainberg, M.D. Associate Clinical Professor of Psychiatry College of Physicians and Surgeons Columbia University firstname.lastname@example.org
Medical Cannabis: A Patient Primer This primer is meant for documented patients who are using medicinal cannabis or considering using it in the future. The information provided about this medication in
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
Cannabis in the treatment of Autism: Are we ready? Deb Karhson, PhD and Lawrence Fung, MD, PhD Cannabis Anecdotal Data: Comparing Epilepsy and Autism+ Science of Cannabinoids: Endocannabinoid System Receptor
A Patient s Guide: Understanding Posttraumatic Stress Disorder and Acute Stress Disorder Department of Veterans Affairs and Department of Defense (DoD) employees who use this information are responsible
CBD and Your Health. Cannabidiol (CBD) is a molecule found in plant species such as agricultural (or industrial) hemp, and Echinacea. CBD is one of at least 489 distinct compounds within hemp: it is clear
Evidence-Based Treatments for Combat-Related PTSD and TBI Alan L. Peterson, PhD University of Texas Health Science Center at San Antonio South Texas Veterans Health Care System Overview Since 2001, almost
Medical Cannabis and OMT David R. Beatty, DO Professor of Osteopathic Principles and Practice, WVSOM November 4, 2017 Objectives At the completion of this presentation the attendee should be able to: 1.
Minnesota Medical Cannabis Program October 24, 2017 Agenda: Overview of Minnesota Medical Cannabis Program Conditions, roles, products Laboratory Issues Program Evaluation * indicates a hyper-link to website
Scottsdale Certification Center Health History Questionnaire Name Gender M / F Date Date of Birth / / Phone Ht: ft in Wt Email Residential Address City State Zip Code Drivers Licence # Date Issued Mailing
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: SCREENING, DIFFERENTIAL DIAGNOSIS, TREATMENT MONITORING DEB COWLEY MD OCTOBER 20, 2016 OBJECTIVES At the
Medicinal cannabis use among PLWH in the era of legalization June 8, 2017 David Grelotti, MD Assistant Professor University of California, San Diego Center for Medicinal Cannabis Research Outline Overview
Minnesota Medical Cannabis Program: Patient Experiences from the First Program Year Executive Summary EXECUTIVE SUMMARY EARLY RELEASE COMPLETE REPORT RELEASE EXPECTED JUNE 2017 May 11, 2017 111n Minnesota
Annual Report 3,4-methylenedioxymethamphetamine (MDMA) IND 063384 Form 1571 Serial Number: 0060 Sequential Number 08 Reporting Period: October 2, 2014 to October 1, 2015 Version Date: January 4, 2016 SPONSOR
Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective John A. Myers and Colin B. Findlay SCG Legal Annual General Meeting September 16, 2016 Boston Licensed
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
1 Medical vs Recreational Use of Cannabis 11 th December 2017 2 Defining Cannabis and Chemical Constituents Cannabis is a plant species. Two main Cannabis sub-species are Cannabis Sativa and Cannabis Indica.
Substances under Surveillance The following substances are under surveillance by the World Health Organization (WHO) as they are considered to have the potential to cause public health harm. For ease of
Anxiety Disorders Anxiety disorders are the most common mental illness in America. More than 19 million Americans suffer from anxiety disorders, which include panic disorder, obsessive-compulsive disorder,
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
Year 9 Cannabis Quiz Answers and Background information Knowledge These questions have been designed to establish your student s knowledge of cannabis. Questions are asked on the legal status of cannabis,
PSYCHOLOGICAL DISORDERS CHAPTER 13 MEYERS AND DEWALL OVERVIEW What are Psychological Disorders? Anxiety Disorders, OCD, and PTSD Substance Use and Addictive Disorders Mood Disorders Schizophrenia Additional
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
Psychoactive drugs Drugs which affect mental processes mood, perception, memory, state of consciousness May be illegal: Heroin Cocaine Legal: Alcohol nicotine Legal but restricted (by prescription only)
MEMBERSHIP PACKAGE MEMBERSHIP OVERVIEW Welcome to Warmland Medicinal Cannabis Centre. Our aim is to provide a consistent, safe, local and dependable source of medicinal cannabis for people suffering from
INSOMNIAS INSOMNIAS General criteria for insomnia A. Repeated difficulty with sleep initiation, duration, consolidation or quality. B. Adequate sleep opportunity, persistent sleep difficulty and associated
American Cannabis Nurses Association Position Statement on Concurrent Cannabis and Opiate Use August 4, 2013; Author: Ed Glick Introduction The American Cannabis Nurses Association supports the monitored
Marijuana Cannabinoid Reception in the Brain Levi van Tol 2/16/2015 Cellular Neuroscience van Tol 1 Books, movies, songs, politics, schools, and just about every corner we turn to, marijuana is a hot topic
Post-Traumatic Stress Disorder (PTSD) in the military and veterans When people think of mental illness in the military it is unsurprising that many of them think of Post-Traumatic Stress Disorder (PTSD),
PATIENT QUESTIONNAIRE Personal Information Date Name Date of Birth Age Height Weight Address City State Zip Home Phone Cell phone Work phone E-mail address SSN: - - Medical History - you must enter information
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
New Criteria for Posttraumatic Stress Disorder in DSM-5: Implications for Causality Paul A. Arbisi, Ph.D. ABAP, ABPP. Staff Psychologist Minneapolis VA Medical Center Professor Departments of Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
Activation-synthesis hypothesis Suggests that in the brain engages in a lot of neural activity that is random. Dreams make sense of this activity. Addition compulsive drug craving and use, despite adverse
Cannabis Dr.Eva Hoch, Dr.Chris Maria Friemel Clinic of Ludwig-Maximilian-University Munich Tuesday 24th October 2017 CANNABIS: LEGAL SITUATION IN EUROPE Clinic of Ludwig Maximilian University, MUNICH LEGISLATIONAL
From Opioid Replacement to Managing Chronic Pain: What is CBD? Kalev Freeman, MD PhD Assistant Professor of Surgery and Pharmacology, University of Vermont Laura Mann Integrative Healthcare Lecture Series
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
Insomnia Teofilo Lee-Chiong MD Professor of Medicine National Jewish Health University of Colorado Denver School of Medicine Learning Objectives Learn about the causes of transient and chronic Learn how
MARIJUANA PREVENTION TOOLKIT KNOW THE FACTS MARIJUANA PREVENTION TOOLKIT United Way of Broward County Commission on Substance Abuse has developed this Toolkit as part of Prevention in a Box to bring relevant
ALVIN C. BURSTEIN, MD PATIENT CLIENT INFORMATION LEGAL Name Date of Birth (must match insurance card) Address City State Zip Mailing Address City State Zip (If different) Phone: Cell Home Appt. reminders
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
MEDICAL CANNABIS QUICK REFERENCE GUIDE CANNABIS 101: MEDICINE MEDICAL CANNABIS QUICK REFERENCE GUIDE HOW IT WORKS DEFINITIONS Cannabinoids Class of compounds that act on cannabinoid receptors in the human
Annual Report 3,4-methylenedioxymethamphetamine (MDMA) IND 063384 1571 Serial Number 0069 Sequential Number 09 Reporting Period: 02 October 2015 to 01 October 2016 Date of Report: 27 December 2016 SPONSOR
Cannabis Use in Epilepsy: Parent & Scientist Weighs In Catherine Jacobson, PhD Director, Clinical Research Professional Background PhD, Neuroscience, Oregon Health & Science University Post-doctoral Fellowship,
MINNESOTA S MEDICAL CANNABIS PROGRAM DARIN TESKE LEGAL AND POLICY ADVISOR OFFICE OF MEDICAL CANNABIS AUGUST 25, 2016 2014: MN became 22 nd state with full medical cannabis program Recreational and Medical
Employee Substance Abuse Program ConocoPhillips Canada June 2011 1 Table of Contents A. Introduction. 3 B. Interpretation. 3 C. Program Statement. 3 D. Supervisor Responsibilities 5 E. Support for ConocoPhillips
The challenge of climbing Mt. Everest: Malignant pain management in the opioid tolerant patient Holly Swensen, MSN, APRN NP c, RN BC Pain Management St. Alphonsus Regional Medical Center Cancer Care Center
1. Medical Condition Neuropathic pain is defined as pain that results from a lesion or disease in the somatosensory system. Neuropathic pain is frequently difficult to treat, and commonly interferes with
THE ADDICTED BRAIN: WHAT S GOING ON IN THERE? 3 CE hours Sandra Morgenthal, PCC-S, CCFC, RN Copyright 2016 Sandra Morgenthal All rights Reserved You can contact this author at email@example.com
Reefer Mania: The State of Medical Marijuana in Florida Amanda G. Chafin Amanda.firstname.lastname@example.org Brief History of Medical Marijuana in Florida May 2014 Legislature approves Compassionate Medical Cannabis
Part I: Nick Jikomes The cannabis plant Cannabinoids & psychoactivity Outline Part II: John Hatch Marijuana and human health Part III: Kayla Davis Public policy and medical marijuana The cannabis plant:
Marijuana Kirk Carruthers, MD Assistant Professor - Clinical Department of Psychiatry The Ohio State University Wexner Medical Center Marijuana (Cannabis Use Disorder) Learning Goals/Objectives Discuss
MANAGEMENT OF VISCERAL PAIN William D. Chey, MD, FACG Professor of Medicine University of Michigan 52 year old female with abdominal pain 5 year history of persistent right sided burning/sharp abdominal
Oncology Pharmacy Navigator: A Novel Model for Medication Management Kelly Rice, Pharm.D. Oncology Pharmacy Navigator Legacy Cancer Institute Portland, Oregon Objectives Understand the role of an oncology
Marijuana for Medical Use Patient Information Marijuana for Medical Use Patient Information Table of Contents Page A. Marijuana (Cannabis) Strains... 3 B. Cannabinoids... 3 C. Routes of Administration...
Cannabis Legalization and Regulation in British Columbia Discussion Paper Introduction In 2015, the federal government committed to legalizing non-medical cannabis in Canada. On June 30, 2016, it established
Reducing Opioid Deaths: Arizona s Emergency Declaration & Response September 15, 2017 Sheila Sjolander, Assistant Director Arizona Department of Health Services Emergency Declaration On June 5, 2017, Arizona